Articles

Search Articles

Advanced search
Help

Catalogue

Articles

Databases

X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (681) 681
humans (601) 601
heart failure (523) 523
cardiac & cardiovascular systems (519) 519
reduced ejection fraction (431) 431
female (375) 375
male (361) 361
mortality (316) 316
heart failure with reduced ejection fraction (284) 284
middle aged (281) 281
aged (274) 274
adult (158) 158
heart failure - physiopathology (157) 157
prognosis (157) 157
treatment outcome (142) 142
risk factors (140) 140
outcomes (130) 130
cardiology (124) 124
transplantation (122) 122
care and treatment (121) 121
heart failure with preserved ejection fraction (121) 121
hematology (120) 120
analysis (119) 119
cardiac patients (115) 115
heart (112) 112
cardiovascular (101) 101
survival (100) 100
therapy (98) 98
heart failure - drug therapy (95) 95
heart diseases (94) 94
aged, 80 and over (93) 93
patients (92) 92
retrospective studies (92) 92
oncology (87) 87
prospective studies (83) 83
health aspects (82) 82
abridged index medicus (81) 81
association (81) 81
echocardiography (78) 78
follow-up studies (77) 77
heart failure - diagnosis (77) 77
medicine & public health (77) 77
article (76) 76
stroke volume (76) 76
heart failure - therapy (75) 75
heart-failure (75) 75
heart failure - mortality (74) 74
trial (73) 73
transplantation conditioning - methods (72) 72
immunology (70) 70
preserved ejection fraction (69) 69
hypertension (68) 68
myocardial-infarction (67) 67
risk (67) 67
research (66) 66
stroke volume - physiology (66) 66
diagnosis (63) 63
management (63) 63
guidelines (62) 62
hospitalization (62) 62
time factors (62) 62
pharmacology & pharmacy (61) 61
animals (57) 57
enalapril (57) 57
morbidity (57) 57
adolescent (55) 55
hematopoietic stem cells (54) 54
medical research (54) 54
prevalence (54) 54
cardiomyopathy (53) 53
clinical trials (53) 53
patient outcomes (53) 53
transplantation, homologous (53) 53
disease (52) 52
left-ventricular dysfunction (52) 52
survival analysis (52) 52
acute myocardial-infarction (51) 51
biomarkers (51) 51
heart failure - epidemiology (51) 51
stem cells (51) 51
bone-marrow-transplantation (50) 50
medical colleges (49) 49
reduced cardiotoxicity (49) 49
young adult (49) 49
cardiovascular disease (48) 48
medicine, experimental (48) 48
medicine, general & internal (48) 48
task-force (47) 47
beta blockers (46) 46
comorbidity (46) 46
hematology, oncology and palliative medicine (46) 46
epidemiology (45) 45
heart failure - blood (45) 45
internal medicine (45) 45
peripheral vascular disease (45) 45
survival rate (45) 45
medicine (44) 44
angiotensin (43) 43
biomarkers - blood (43) 43
chemotherapy (43) 43
more...
Library Location Library Location
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (1130) 1130
Russian (7) 7
German (6) 6
Czech (3) 3
Portuguese (3) 3
French (2) 2
Polish (2) 2
Chinese (1) 1
Korean (1) 1
Slovak (1) 1
Spanish (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


1. Full Text Medical Therapy for Heart Failure With Reduced Ejection Fraction: The CHAMP-HF Registry
by Greene, Stephen J and Butler, Javed and Albert, Nancy M and DeVore, Adam D and Sharma, Puza P and Duffy, Carol I and Hill, C. Larry and McCague, Kevin and Mi, Xiaojuan and Patterson, J. Herbert and Spertus, John A and Thomas, Laine and Williams, Fredonia B and Hernandez, Adrian F and Fonarow, Gregg C
Journal of the American College of Cardiology, ISSN 0735-1097, 07/2018, Volume 72, Issue 4, pp. 351 - 366
Background: Guidelines strongly recommend patients with heart failure with reduced ejection fraction (HFrEF) be treated with multiple medications proven to... 
reduced ejection fraction | registry | dose | medication | Severity of Illness Index | Mineralocorticoid Receptor Antagonists - administration & dosage | United States - epidemiology | Age Factors | Humans | Middle Aged | Heart Failure - physiopathology | Male | Socioeconomic Factors | Heart Failure - drug therapy | Mineralocorticoid Receptor Antagonists - therapeutic use | Dose-Response Relationship, Drug | Stroke Volume | Quality Improvement | Registries - statistics & numerical data | Female | Aged | Angiotensin Receptor Antagonists - therapeutic use | Heart Failure - epidemiology | Adrenergic beta-Antagonists - administration & dosage | Drug Utilization - statistics & numerical data | Adrenergic beta-Antagonists - therapeutic use | Angiotensin Receptor Antagonists - administration & dosage | Practice Guidelines as Topic | Heart failure | Care and treatment | Enzyme inhibitors | Analysis | Cardiac patients | Health care | Angiotensin-converting enzyme inhibitors | Drugs | Therapy | Cardiac arrhythmia | Medical services | Medical records | Clinical trials | Cardiovascular disease | Secondary schools | Regulatory approval | Renal insufficiency | Peptidyl-dipeptidase A | Blood pressure | Cardiology | Angiotensin II | Heart diseases | Age | Hypertension | Mortality | Hospitalization | Patients | Asthma | Heart rate | Ethnicity | Inhibitors | Coronary vessels | Angiotensin | Neprilysin | Diabetes | Clinical medicine | Females | Hispanics | Ejection
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
2. Full Text Effect of Natriuretic Peptide–Guided Therapy on Hospitalization or Cardiovascular Mortality in High-Risk Patients With Heart Failure and Reduced Ejection Fraction: A Randomized Clinical Trial
by Felker, G. Michael and Anstrom, Kevin J and Adams, Kirkwood F and Ezekowitz, Justin A and Fiuzat, Mona and Houston-Miller, Nancy and Januzzi, James L and Mark, Daniel B and Piña, Ileana L and Passmore, Gayle and Whellan, David J and Yang, Hongqiu and Cooper, Lawton S and Leifer, Eric S and Desvigne-Nickens, Patrice and O’Connor, Christopher M
JAMA, ISSN 0098-7484, 08/2017, Volume 318, Issue 8, pp. 713 - 720
IMPORTANCE: The natriuretic peptides are biochemical markers of heart failure (HF) severity and predictors of adverse outcomes. Smaller studies have evaluated... 
IMPROVE | MEDICINE, GENERAL & INTERNAL | TIME | MANAGEMENT | MORBIDITY | CARE | Single-Blind Method | Humans | Middle Aged | Ventricular Dysfunction - drug therapy | Heart Failure - physiopathology | Hospitalization - statistics & numerical data | Male | Biomarkers - blood | Heart Failure - blood | Heart Failure - drug therapy | Stroke Volume | Heart Failure - therapy | Treatment Failure | Peptide Fragments - blood | Cardiovascular Diseases - mortality | Female | Aged | Natriuretic Peptide, Brain - blood | Heart failure | Heart | Brain natriuretic peptide | Therapy | Peptides | Risk groups | Mortality | Clinical trials | Patients | Risk factors | Randomization | Safety engineering | Biomarkers | Strategy | Titration | Drug therapy | Cardiovascular diseases | Heart diseases | Ejection | Biochemical markers | heart failure with reduced ejection fraction | amino-terminal pro–B-type natriuretic peptide | patient outcomes
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
3. Full Text Determinants of exercise intolerance in patients with heart failure and reduced or preserved ejection fraction
by Haykowsky, Mark J and Tomczak, Corey R and Scott, Jessica M and Paterson, D. Ian and Kitzman, Dalane W
Journal of Applied Physiology, ISSN 8750-7587, 09/2015, Volume 119, Issue 6, pp. 739 - 744
This mini-review summarizes the literature regarding the mechanisms of exercise intolerance in patients with heart failure and reduced or preserved ejection... 
Heart failure and reduced ejection fraction | Exercise physiology | Heart failure and preserved ejection fraction | CAPACITY | SPORT SCIENCES | heart failure and reduced ejection fraction | PHYSIOLOGY | exercise physiology | VENTRICULAR SYSTOLIC FUNCTION | OXYGEN-TRANSPORT | BLOOD-FLOW | ENDOTHELIAL FUNCTION | HEMODYNAMIC-RESPONSE | AMBULATORY PATIENTS | SKELETAL-MUSCLE CHANGES | NUTRITIVE FLOW | OLDER PATIENTS | heart failure and preserved ejection fraction | Exercise - physiology | Muscle, Skeletal - physiology | Oxygen Consumption - physiology | Exercise Tolerance - physiology | Humans | Heart Failure - physiopathology | Highlighted Topic
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
4. Full Text Impact of Noncardiac Comorbidities on Morbidity and Mortality in a Predominantly Male Population With Heart Failure and Preserved Versus Reduced Ejection Fraction
by Ather, Sameer, MD and Chan, Wenyaw, PhD and Bozkurt, Biykem, MD, PhD and Aguilar, David, MD and Ramasubbu, Kumudha, MD and Zachariah, Amit A., MD and Wehrens, Xander H.T., MD, PhD and Deswal, Anita, MD, MPH
JACC (Journal of the American College of Cardiology), ISSN 0735-1097, 2012, Volume 59, Issue 11, pp. 998 - 1005
Objectives The aim of this study was to evaluate the prevalence and prognostic impacts of noncardiac comorbidities in patients with heart failure (HF) with... 
Cardiovascular | Internal Medicine | heart failure with preserved ejection fraction | comorbidities | heart failure with reduced ejection fraction | prognosis | diastolic heart function | COMMUNITY PERSPECTIVE | CARDIAC & CARDIOVASCULAR SYSTEMS | VENTRICULAR SYSTOLIC FUNCTION | DEATH | DISEASE | COHORT | HOSPITALIZATIONS | OUTCOMES | EPIDEMIOLOGY | REGISTRY | Stroke Volume | United States - epidemiology | Prevalence | Comorbidity | Humans | Middle Aged | Aged, 80 and over | Female | Male | Aged | Retrospective Studies | Heart Failure - mortality | Heart failure | Patient outcomes | Mortality | Respiratory tract diseases | Diabetes | Health aspects | Public health | Medical colleges | Chronic obstructive pulmonary disease | Heart attacks | Drug therapy | Chronic illnesses
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
5. Full Text Macrophages in Heart Failure with Reduced versus Preserved Ejection Fraction
by DeBerge, Matthew and Shah, Sanjiv J and Wilsbacher, Lisa and Thorp, Edward B
Trends in Molecular Medicine, ISSN 1471-4914, 04/2019, Volume 25, Issue 4, pp. 328 - 340
There is a growing number of individuals living with heart failure (HF) with reduced ejection fraction (HFrEF) or preserved ejection fraction (HFpEF).... 
preserved ejection fraction | heart failure | reduced ejection fraction | macrophage | inflammation | FIBROBLAST PRECURSORS | MEDICINE, RESEARCH & EXPERIMENTAL | RESIDENT CARDIAC MACROPHAGES | TYROSINE KINASE | BIOCHEMISTRY & MOLECULAR BIOLOGY | BONE-MARROW | DIASTOLIC DYSFUNCTION | CELL BIOLOGY | INFLAMMATION | ACUTE MYOCARDIAL-INFARCTION | GENE-EXPRESSION | DOUBLE-BLIND | STEADY-STATE
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
6. Full Text Recovered heart failure with reduced ejection fraction and outcomes: a prospective study
by Lupón, Josep and Díez‐López, Carles and de Antonio, Marta and Domingo, Mar and Zamora, Elisabet and Moliner, Pedro and González, Beatriz and Santesmases, Javier and Troya, Maria I and Bayés‐Genís, Antoni
European Journal of Heart Failure, ISSN 1388-9842, 12/2017, Volume 19, Issue 12, pp. 1615 - 1623
Aims Significant recovery of left ventricular ejection fraction (LVEF) occurs in a proportion of patients with heart failure (HF) and reduced ejection fraction... 
Heart failure with preserved ejection fraction | Recovered | Heart failure with reduced ejection fraction | Heart failure with mid‐range ejection fraction | Left ventricular ejection fraction | Heart failure with mid-range ejection fraction | DIAGNOSIS | CARDIAC & CARDIOVASCULAR SYSTEMS | COMMUNITY | PROGNOSIS | COLLABORATION | PREVALENCE | ENALAPRIL
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
7. Full Text Titration of Medical Therapy for Heart Failure With Reduced Ejection Fraction
by Greene, SJ and Fonarow, GC and DeVore, AD and Sharma, PP and Vaduganathan, M and Albert, NM and Duffy, CI and Hill, L and McCague, K and Patterson, JH and Spertus, JA and Thomas, L and Williams, FB and Hernandez, AF and Butler, J
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, ISSN 0735-1097, 05/2019, Volume 73, Issue 19, pp. 2365 - 2383
BACKGROUND Guidelines recommend that patients with heart failure with reduced ejection fraction (HFrEF) have medical therapy titrated to target doses derived... 
SURVIVAL | heart failure | reduced ejection fraction | registry | dose | CARDIAC & CARDIOVASCULAR SYSTEMS | MANAGEMENT | medication | ENALAPRIL | Heart failure | Care and treatment | Analysis | Cardiac patients | Angiotensin-converting enzyme inhibitors | Heart | Drugs | Therapy | Identification methods | Clinical trials | Cardiovascular disease | Secondary schools | Multivariate analysis | Beta blockers | Confidence intervals | Enzyme inhibitors | Peptidyl-dipeptidase A | Education | Blood pressure | Angiotensin II | Heart diseases | Medical research | Family income | Enrollments | Hospitalization | Patients | Quality of life | Ethnicity | Inhibitors | Quality control | Angiotensin | Titration | Neprilysin | Clinical medicine | Ejection
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
8. Full Text Sex and Race Differences in Lifetime Risk of Heart Failure With Preserved Ejection Fraction and Heart Failure With Reduced Ejection Fraction
by Pandey, Ambarish and Omar, Wally and Ayers, Colby and LaMonte, Michael and Klein, Liviu and Allen, Norrina B and Kuller, Lewis H and Greenland, Philip and Eaton, Charles B and Gottdiener, John S and Lloyd-Jones, Donald M and Berry, Jarett D
Circulation, ISSN 0009-7322, 04/2018, Volume 137, Issue 17, pp. 1814 - 1823
BACKGROUND:Lifetime risk of heart failure has been estimated to range from 20% to 46% in diverse sex and race groups. However, lifetime risk estimates for the... 
heart failure | risk | CARDIAC & CARDIOVASCULAR SYSTEMS | MANAGEMENT | ATHEROSCLEROSIS | SYSTOLIC FUNCTION | PREVALENCE | PREDICTORS | DISEASE | PERIPHERAL VASCULAR DISEASE | OUTCOMES | DYSFUNCTION | EPIDEMIC | ASSOCIATION | Heart failure | Genetic aspects | Cardiac output | Research | Risk factors | Heart failure with preserved ejection fraction | Lifetime risk | Heart failure with reduced ejection fraction
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
9. Full Text Medical Therapy for Heart Failure With Reduced Ejection Fraction
by Greene, Stephen J and Butler, Javed and Albert, Nancy M and DeVore, Adam D and Sharma, Puza P and Duffy, Carol I and Hill, C. Larry and McCague, Kevin and Mi, Xiaojuan and Patterson, J. Herbert and Spertus, John A and Thomas, Laine and Williams, Fredonia B and Hernandez, Adrian F and Fonarow, Gregg C
Journal of the American College of Cardiology, ISSN 0735-1097, 07/2018, Volume 72, Issue 4, pp. 351 - 366
Guidelines strongly recommend patients with heart failure with reduced ejection fraction (HFrEF) be treated with multiple medications proven to improve... 
reduced ejection fraction | registry | dose | medication | MORTALITY | CARDIAC & CARDIOVASCULAR SYSTEMS | MANAGEMENT | IMPROVE HF | OPTIMAL IMPLEMENTATION | RISK | PREVALENCE | CARE | CARDIOLOGY PRACTICES | REDUCTION | OUTCOMES
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
10. Full Text Factors associated with underuse of mineralocorticoid receptor antagonists in heart failure with reduced ejection fraction: an analysis of 11 215 patients from the Swedish Heart Failure Registry
by Savarese, Gianluigi and Carrero, Juan‐Jesus and Pitt, Bertram and Anker, Stefan D and Rosano, Giuseppe M.C and Dahlström, Ulf and Lund, Lars H and Avdelningen för kardiovaskulär medicin and Medicinska fakulteten and Region Östergötland and Linköpings universitet and Institutionen för medicin och hälsa and Hjärt- och Medicincentrum and Kardiologiska kliniken US
European Journal of Heart Failure, ISSN 1388-9842, 09/2018, Volume 20, Issue 9, pp. 1326 - 1334
Aim Mineralocorticoid receptor antagonists (MRAs) improve outcomes in heart failure with reduced ejection fraction (HFrEF), but are underutilized.... 
Hyperkalaemia | Heart failure with reduced ejection fraction | Mineralocorticoid receptor antagonists | Guidelines | MORTALITY | SURVIVAL | MILD PATIENTS HOSPITALIZATION | CARDIAC & CARDIOVASCULAR SYSTEMS | MANAGEMENT | HYPERKALEMIA | THERAPY | SPIRONOLACTONE | EPLERENONE | WORSENING RENAL-FUNCTION | Kardiologi | Clinical Medicine | Cardiac and Cardiovascular Systems | Medical and Health Sciences | Medicin och hälsovetenskap | Klinisk medicin
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
11. Full Text Cost-effectiveness of sacubitril/valsartan in the treatment of heart failure with reduced ejection fraction
by McMurray, John J V and Trueman, David and Hancock, Elizabeth and Cowie, Martin R and Briggs, Andrew and Taylor, Matthew and Mumby-Croft, Juliet and Woodcock, Fionn and Lacey, Michael and Haroun, Rola and Deschaseaux, Celine
Heart, ISSN 1355-6037, 06/2018, Volume 104, Issue 12, pp. 1006 - 1013
ObjectiveChronic heart failure with reduced ejection fraction (HF-REF) represents a major public health issue and is associated with considerable morbidity and... 
quality and outcomes of care | NATIONAL-HEALTH-SERVICE | STATES | CARDIAC & CARDIOVASCULAR SYSTEMS | CARDIOMYOPATHY | health care economics | heart failure with reduced ejection fraction | ENALAPRIL | VALSARTAN | Health Care Delivery, Economics and Global Health Care | 1506
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
12. Full Text Digoxin Discontinuation and Outcomes in Patients With Heart Failure With Reduced Ejection Fraction
by Malik, Awais and Masson, Ravi and Singh, Steven and Wu, Wen-Chih and Packer, Milton and Pitt, Bertram and Waagstein, Finn and Morgan, Charity J and Allman, Richard M and Fonarow, Gregg C and Ahmed, Ali and Sahlgrenska akademin and Institute of Medicine and Göteborgs universitet and Gothenburg University and Sahlgrenska Academy and Institutionen för medicin
Journal of the American College of Cardiology, ISSN 0735-1097, 08/2019, Volume 74, Issue 5, pp. 617 - 627
The deleterious effects of discontinuation of digoxin on outcomes in ambulatory patients with chronic heart failure (HF) with reduced ejection fraction (HFrEF)... 
mortality | heart failure | reduced ejection fraction | digoxin discontinuation | readmission | CARDIAC & CARDIOVASCULAR SYSTEMS | PROPENSITY SCORE | RENIN-ANGIOTENSIN INHIBITION | HOSPITALIZATION | MILD | OPTIMIZE-HF | SUBGROUP ANALYSIS | KIDNEY | WITHDRAWAL | ASSOCIATION | Heart failure | Medical research | Enzymes | Care and treatment | Digoxin | Patient outcomes | Mortality | African Americans | Homeopathy | Materia medica and therapeutics | Cardiac patients | Therapeutics | Medicine, Experimental | Angiotensin-converting enzyme inhibitors | Heart | Clinical trials | Beta blockers | Patients | Discharge | Confidence intervals | Enzyme inhibitors | Peptidyl-dipeptidase A | Government programs | Angiotensin | Blood pressure | Health risk assessment | Heart diseases | Ejection | hospitalization | subgroup analysis | mild | association | withdrawal | optimize-hf | Kardiologi | kidney | Cardiac and Cardiovascular Systems | Cardiovascular System & Cardiology | renin-angiotensin inhibition | propensity score
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
13. Full Text Physicians' guideline adherence is associated with better prognosis in outpatients with heart failure with reduced ejection fraction: the QUALIFY international registry
by Komajda, Michel and Cowie, Martin R and Tavazzi, Luigi and Ponikowski, Piotr and Anker, Stefan D and Filippatos, Gerasimos S and QUALIFY Investigators
European Journal of Heart Failure, ISSN 1388-9842, 11/2017, Volume 19, Issue 11, pp. 1414 - 1423
Aims To evaluate the impact of physicians' adherence to guideline‐recommended medications for heart failure with reduced ejection fraction (HFrEF), including... 
Adherence | Medication | Heart failure with reduced ejection fraction | Dosage | Outcomes | Guidelines | Morbidity - trends | Prognosis | Prospective Studies | Follow-Up Studies | Global Health | Humans | Middle Aged | Heart Failure - physiopathology | Stroke Volume - physiology | Male | Practice Patterns, Physicians | Drug Prescriptions - standards | Mineralocorticoid Receptor Antagonists - therapeutic use | Heart Failure - therapy | Guideline Adherence | Outpatients | Angiotensin-Converting Enzyme Inhibitors - therapeutic use | Physicians - standards | Female | Registries | Angiotensin Receptor Antagonists - therapeutic use | Heart Failure - epidemiology | Adrenergic beta-Antagonists - therapeutic use
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
14. Full Text Frequent premature ventricular complexes and normal ejection fraction: to treat or not to treat?
by Roca-Luque, Ivo and Mont, Lluis
Heart, ISSN 1355-6037, 09/2019, Volume 105, Issue 18, pp. 1386 - 1387
[...]previous studies have established a correlation between the frequency of PVC and LVEF deterioration3 5 and a lower probability for LVEF recovery after PVC... 
premature ventricular beats | CARDIAC & CARDIOVASCULAR SYSTEMS | HEALTHY-SUBJECTS | heart failure with reduced ejection fraction | ventricular arrhythmia ablation procedures | CONTRACTIONS | Studies | Heart failure | Transplants & implants | Cardiomyopathy | Mortality | Cardiovascular disease | Patients
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
15. Full Text Digoxin Use and Outcomes in Patients with Heart Failure with Reduced Ejection Fraction
by Qamer, Syed Z and Malik, Awais and Bayoumi, Essraa and Lam, Phillip H and Singh, Steven and Packer, Milton and Kanonidis, Ioannis E and Morgan, Charity J and Abdelmawgoud, Ahmed and Allman, Richard M and Fonarow, Gregg C and Ahmed, Ali
The American journal of medicine, ISSN 0002-9343, 05/2019
Heart failure is a leading cause for hospital readmission. Digoxin use may lower this risk in patients with heart failure with reduced ejection fraction... 
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
16. Full Text What Have We Learned About Patients With Heart Failure and Preserved Ejection Fraction From DIG-PEF, CHARM-Preserved, and I-PRESERVE?
by Campbell, Ross T., MB ChB, BSc and Jhund, Pardeep S., MB ChB, PhD and Castagno, Davide, MD and Hawkins, Nathaniel M., MB ChB, MD and Petrie, Mark C., MB ChB, BSc and McMurray, John J.V., MD
JACC (Journal of the American College of Cardiology), ISSN 0735-1097, 2012, Volume 60, Issue 23, pp. 2349 - 2356
Examination of patients with reduced and preserved ejection fraction in the DIG (Digitalis Investigation Group) trials and the CHARM (Candesartan in Heart... 
Cardiovascular | Internal Medicine | preserved ejection fraction | heart failure | reduced ejection fraction | outcomes | MORTALITY | CARDIAC & CARDIOVASCULAR SYSTEMS | BRAIN NATRIURETIC PEPTIDE | VENTRICULAR SYSTOLIC FUNCTION | RANDOMIZED-TRIAL | CLINICAL CHARACTERISTICS | CARDIOVASCULAR MORBIDITY | HYPERTENSIVE PATIENTS | CONVERTING-ENZYME INHIBITORS | LIFE | Survival Rate - trends | Global Health | Angiotensin II Type 1 Receptor Blockers - therapeutic use | Humans | Heart Failure - physiopathology | Stroke Volume - physiology | Clinical Trials as Topic | Biphenyl Compounds - therapeutic use | Heart Failure - drug therapy | Cardiotonic Agents - therapeutic use | Tetrazoles - therapeutic use | Benzimidazoles - therapeutic use | Heart Failure - mortality | Heart failure | Hypertension | Enzymes | Comorbidity | Analysis | Atrial fibrillation | Cardiac patients | Diabetes | Coronary heart disease | Mortality | Cardiovascular disease | Heart attacks | Drug therapy
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights